Engineered Tcells for pancreatic cancer treatment
- 30 September 2011
- journal article
- Published by Elsevier BV in HPB
- Vol. 13 (9), 643-650
- https://doi.org/10.1111/j.1477-2574.2011.00344.x
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical ExperienceJournal of Clinical Oncology, 2006
- Anti–Prostate Stem Cell Antigen Monoclonal Antibody 1G8 Induces Cell Death In vitro and Inhibits Tumor Growth In vivo via a Fc-Independent MechanismCancer Research, 2005
- Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic CancerPancreas, 2005
- Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cellsBlood, 2004
- Genetic Modification of T Lymphocytes for Adoptive ImmunotherapyMolecular Therapy, 2004
- Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2 + patients with hormone-refractory prostate cancerCancer Immunology, Immunotherapy, 2004
- A prostate stem cell antigen‐derived peptide immunogenic in HLA‐A24− prostate cancer patientsThe Prostate, 2004
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic MelanomaJournal of Immunotherapy, 2001